Could Regeneron Pharmaceuticals Stock Help You Become a Millionaire?

Regeneron Pharmaceuticals (NASDAQ: REGN) is a top pharmaceutical company with many promising assets in its portfolio. Its diverse business has enabled the business to grow over the years. In the past decade, the stock has risen by more than 185%, outperforming the S 500's 155% gain over the same stretch. With more growth still on the way, can this be an investment that helps make you a millionaire in the future?

Regeneron's business centers around its eye medication, Eylea, which treats wet age-related macular degeneration. It recently obtained approval for a higher-dose (8 mg) version of the drug, which bolsters its growth prospects. Otherwise, its prospects would have been concerning, with cheaper biosimilars entering the market next year to compete alongside the standard dose (2 mg).

But Regeneron's business is broader than just Eylea. If it weren't, the company's results wouldn't be as impressive as they are. In its most recent quarter, for the period ended Sept. 30, Regeneron brought in $3.4 billion in revenue, which was up 15% year over year. Collaboration revenue has been a key driver for the company of late as agreements with Sanofi and Bayer have allowed Regeneron to grow despite lackluster product sales during the quarter, which were down 1% year over year. Sales of the standard-dose Eylea were down 11%, falling to $1.4 billion.

Continue reading

Source Fool.com